These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 26781865)
21. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964 [TBL] [Abstract][Full Text] [Related]
22. Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP". Mayer KH; Safren SA; Elsesser SA; Psaros C; Tinsley JP; Marzinke M; Clarke W; Hendrix C; Wade Taylor S; Haberer J; Mimiaga MJ AIDS Behav; 2017 May; 21(5):1350-1360. PubMed ID: 27848089 [TBL] [Abstract][Full Text] [Related]
23. Challenges to PrEP use and perceptions of urine tenofovir adherence monitoring reported by individuals on PrEP. Hunt T; Lalley-Chareczko L; Daughtridge G; Swyryn M; Koenig H AIDS Care; 2019 Oct; 31(10):1203-1206. PubMed ID: 30821473 [TBL] [Abstract][Full Text] [Related]
24. Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010. Kebaabetswe PM; Stirratt MJ; McLellan-Lemal E; Henderson FL; Gray SC; Rose CE; Williams T; Paxton LA AIDS Behav; 2015 May; 19(5):758-69. PubMed ID: 25186785 [TBL] [Abstract][Full Text] [Related]
25. How to "PrEP" for HIV Prevention in Women. Ntim GJ; Kransdorf LN J Womens Health (Larchmt); 2017 Feb; 26(2):195-196. PubMed ID: 28140756 [No Abstract] [Full Text] [Related]
26. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA; AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753 [TBL] [Abstract][Full Text] [Related]
27. Oral preexposure prophylaxis to prevent HIV infection: clinical and public health implications. Baker J; OʼHara KM JAAPA; 2014 Dec; 27(12):10-7. PubMed ID: 25390822 [TBL] [Abstract][Full Text] [Related]
28. Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Glidden DV; Amico KR; Liu AY; Hosek SG; Anderson PL; Buchbinder SP; McMahan V; Mayer KH; David B; Schechter M; Grinsztejn B; Guanira J; Grant RM Clin Infect Dis; 2016 May; 62(9):1172-7. PubMed ID: 26797207 [TBL] [Abstract][Full Text] [Related]
29. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401 [TBL] [Abstract][Full Text] [Related]
30. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Haberer JE Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638 [TBL] [Abstract][Full Text] [Related]
31. Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse. Ebell MH Am Fam Physician; 2016 Mar; 93(6):520. PubMed ID: 26977839 [No Abstract] [Full Text] [Related]
32. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. Antimicrob Agents Chemother; ; . PubMed ID: 26195515 [TBL] [Abstract][Full Text] [Related]